Analysts at Cantor Fitzgerald raised their price target on shares of Newlink Genetics Cor (NASDAQ: NLNK) from $18.00 to $25.00 in a research report issued to clients and investors on Wednesday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 57.83% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Newlink Genetics Cor from $21.00 to $25.00 in a research note to investors on Tuesday, May 7th. They now have a “buy” rating on the stock.
Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $22.13.
Shares of Newlink Genetics Cor (NASDAQ: NLNK) opened at 15.84 on Wednesday. Newlink Genetics Cor has a 52 week low of $10.40 and a 52 week high of $18.00. The stock’s 50-day moving average is currently $12.05. The company’s market cap is $405.6 million.
Newlink Genetics Cor (NASDAQ: NLNK) last announced its earnings results on Monday, May 6th. The company reported ($0.33) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.28) by $0.05. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.41 million. On average, analysts predict that Newlink Genetics Cor will post $-1.37 earnings per share for the current fiscal year.
NewLink Genetics Corporation (NASDAQ: NLNK) is a development-stage company.